About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

UNKNOWNNA

DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

A Prospective, Single-arm Clinical Study on the Efficacy and Safety of DEBIRI Combined With Systemic Chemotherapy and Bevacizumab for Unresectable Colorectal Cancer With Liver Metastases

NCT06177288•Fudan University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Colorectal Neoplasms

Interventions

DEBIRI Combined With Chemotherapy and Bevacizumab

Locations

1

China

Locations (1)

Zhongshan hospital, Fudan university

Shanghai, China

Key Dates

Start Date

January 1, 2024

Primary Completion Date

January 1, 2025

Completion Date

May 1, 2025

Last Updated

December 20, 2023

Related Studies

RECRUITINGPhase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786

Colorectal Neoplasms

RECRUITINGPhase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319

Colorectal NeoplasmsGastrointestinal Neoplasms

RECRUITINGPhase 3

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

NCT05239741

Colorectal Neoplasms

RECRUITINGPhase 2/3

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

NCT05770102

MalignancyMalignant Neoplasm+8 more

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

NCT04812912

Colorectal CancerColorectal Neoplasms+1 more

RECRUITINGPhase 2

Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.

NCT06778382

Colorectal Neoplasms Malignant

View all related studies

Contacts

Jianmin Jianmin, Ph.D

CONTACT

13501984869 xujmin@aliyun.com

Dexiang Zhu, Ph.D

CONTACT

13764353275 shzhudx@163.com

Sponsors

Lead Sponsor

Fudan University

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 20, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions